RxDoctor Payments DataLook up a doctor →

Kelley Hanau, APRN

Psychiatric/Mental Health · Lincoln, NENPI 1225235898

Payments from drug & device makers

$7,897in general payments, 2019–2025

Across 447 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$854
  • Lundbeck LLC$580
  • Gilead$520
  • Supernus Pharmaceuticals, Inc.$416
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$75910%
  • Food & beverage$7,13290%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,897 in reported general payments places this provider in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$63,713
Medicare patients
30
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$114,355
SpravatoEsketamine Hcl77$96,645
VraylarCariprazine Hcl25$37,101
CaplytaLumateperone Tosylate13$21,721
BelsomraSuvorexant35$15,802
Fluvoxamine Maleate41$2,779
Ziprasidone Hcl37$1,816
Haloperidol33$1,425
Divalproex Sodium ErDivalproex Sodium24$1,321
Olanzapine52$1,003
Clomipramine Hcl13$952
Quetiapine Fumarate ErQuetiapine Fumarate27$901
Lamotrigine83$848
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$839
Clonazepam79$801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$28$114,35513 claims
Johnson & JohnsonSpravato$1,297$96,64577 claims
AbbVieVraylar$1,644$37,10125 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$176$21,72113 claims
MerckBelsomra$54$15,80235 claims
Lilly USA, LLCOlanzapine$73$1,00352 claims
Teva Pharmaceuticals USA, Inc.Loxapine$112$61013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →